Coalition Aims to Improve Supportive Cancer Care

Commentary
Video

Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.

Together for Supportive Cancer Care is a collaborative effort between health care organizations to enhance the quality and accessibility of supportive care for patients with cancer. Recognizing the insufficiency of current supportive care services, the coalition aims to improve the overall patient experience by addressing various aspects of care, including physical, psychological, social, and spiritual support.

Andrew T. Leitner, MD, chair in the Department of Supportive Care Medicine, associate clinical professor in the Department of Anesthesiology, and chief in the Division of Interventional Patin Management at City of Hope in Duarte, California, spoke with CancerNetwork® about this new initiative. By sharing best practices, conducting research, and advocating for policy changes, the coalition strives to create a more comprehensive and supportive care environment for patients with cancer and their families.

Transcript:

Together for Supportive Cancer Care came from a recognition that a number of health care organizations are working to advance a common goal and can do it better together. That common goal is the comprehensive support that patients navigating a serious illness—in this case, cancer—need, and the ways that the health care system currently meets those needs is insufficient for the scope and scale of those needs. How do member organizations come together to learn from one another, share best practices, conduct research, and move advocacy toward policy that helps the supportive care provision for patients and their loved ones [with] cancer?

One of the first things the coalition was primed to do was to define terms and the scope of the problem. To start, when we talk about supportive care, we talk broadly about the support of the patient with cancer and their family and community, but that specifically means a constellation of access to various clinical and community services and programs to help manage the various adverse effects of a cancer diagnosis. The coalition first and foremost was establishing a shared set of definitions of what we mean when we say supportive care in cancer or supportive cancer care. Some of the essential components of that include how we assess and manage physical symptoms, how we provide psychological and emotional support, and social and practical support. [Another focus is] a number of the specialty aspects of supportive care in cancer, such as spiritual care, end-of-life care, various rehabilitation services, and integrative therapies. How do we pull all of those together so that they’re well well-coordinated as the patient is navigating our complex health care system?

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.